1. Home
  2. KDLY vs VIRX Comparison

KDLY vs VIRX Comparison

Compare KDLY & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KDLY
  • VIRX
  • Stock Information
  • Founded
  • KDLY 2019
  • VIRX 2007
  • Country
  • KDLY United States
  • VIRX United States
  • Employees
  • KDLY N/A
  • VIRX N/A
  • Industry
  • KDLY
  • VIRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • KDLY
  • VIRX Health Care
  • Exchange
  • KDLY NYSE
  • VIRX Nasdaq
  • Market Cap
  • KDLY 7.8M
  • VIRX 6.3M
  • IPO Year
  • KDLY 2024
  • VIRX N/A
  • Fundamental
  • Price
  • KDLY $1.12
  • VIRX $0.21
  • Analyst Decision
  • KDLY
  • VIRX Buy
  • Analyst Count
  • KDLY 0
  • VIRX 4
  • Target Price
  • KDLY N/A
  • VIRX $5.00
  • AVG Volume (30 Days)
  • KDLY 1.0M
  • VIRX 4.0M
  • Earning Date
  • KDLY 02-03-2025
  • VIRX 11-13-2024
  • Dividend Yield
  • KDLY N/A
  • VIRX N/A
  • EPS Growth
  • KDLY N/A
  • VIRX N/A
  • EPS
  • KDLY N/A
  • VIRX N/A
  • Revenue
  • KDLY $2,875,400.00
  • VIRX N/A
  • Revenue This Year
  • KDLY N/A
  • VIRX N/A
  • Revenue Next Year
  • KDLY N/A
  • VIRX N/A
  • P/E Ratio
  • KDLY N/A
  • VIRX N/A
  • Revenue Growth
  • KDLY N/A
  • VIRX N/A
  • 52 Week Low
  • KDLY $0.65
  • VIRX $0.13
  • 52 Week High
  • KDLY $4.20
  • VIRX $1.31
  • Technical
  • Relative Strength Index (RSI)
  • KDLY N/A
  • VIRX 62.02
  • Support Level
  • KDLY N/A
  • VIRX $0.20
  • Resistance Level
  • KDLY N/A
  • VIRX $0.23
  • Average True Range (ATR)
  • KDLY 0.00
  • VIRX 0.03
  • MACD
  • KDLY 0.00
  • VIRX 0.01
  • Stochastic Oscillator
  • KDLY 0.00
  • VIRX 60.34

About KDLY KINDLY MD INC

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

About VIRX Viracta Therapeutics Inc.

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Share on Social Networks: